“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP TAZ) Lotion”. SKIN The Journal of Cutaneous Medicine 3 (November 9, 2019): S31. Accessed April 18, 2025. https://skin.dermsquared.com/skin/article/view/758.